ClinicalTrials.gg

Program

garetatug rezetecan

Also written as “SHR-A1904”, “SHR-A1904 for Injection” and “SHR-A1904; Adebrelimab”.

In Jiangsu HengRui Medicine’s pipeline, Claudin 18.2 ADC. Its studies are mostly in Biliary Tract Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Oct 17, 20247 company-led studies, 6 open or runningNext primary completion: Sep 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine76 open or runningphase 3since Oct 17, 2024Apr 27, 2021Sep 20, 2027phase 3 · NCT06649292
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-A1904, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2021First study: phase 1 study in Advanced Solid CancerFirst studyNCT04877717 · 107 enrolled · China
  2. Jun 2, 2021Phase 1 study in Advanced Pancreatic CancerNCT04928625 · 75 enrolled · China
  3. Mar 3, 2022Phase 2 study in Advanced Solid TumorsNCT05277168 · 83 planned · United States, Australia, Moldova and more
  4. Apr 1, 2024Phase 1 study in CLDN18.2-positive Advanced Solid TumorNCT06350006 · 924 planned · China
  5. Oct 17, 2024Phase 3 study in Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06649292 · 524 planned · China
  6. Jul 31, 2025Phase 2 study in Stomach NeoplasmsNCT07110571 · 200 planned · China
  7. Feb 27, 2026Phase 2 study in Biliary Tract NeoplasmsNCT07450976 · 151 planned · China

Ahead

  1. Sep 20, 2027Primary completion: phase 3 study in Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06649292
  2. Dec 30, 2027Primary completion: phase 1 study in CLDN18.2-positive Advanced Solid TumorNCT06350006
  3. Dec 2030Primary completion: phase 2 study in Biliary Tract NeoplasmsNCT07450976

TargetBeta

“Claudin 18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of garetatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated, via a cleavable linker, to rezetecan, an exatecan derivative and topoisomerase …”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of garetatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07450976Biliary Tract Neoplasms · China2RecruitingDec 2030151
NCT07110571Stomach Neoplasms · China2RecruitingAug 2026200
NCT06649292Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · China3RecruitingSep 20, 2027524
NCT06350006CLDN18.2-positive Advanced Solid Tumor · China1RecruitingDec 30, 2027924
NCT05277168Advanced Solid Tumors · United States, Australia, Moldova and more2RecruitingMay 202683
NCT04928625Advanced Pancreatic Cancer · China1UNKNOWNJun 30, 202375
NCT04877717Advanced Solid Cancer · China1Active, not recruitingDec 1, 2025107

How it is read

Names in the registry

  • “SHR-A1904”, 4 entries
  • “SHR-A1904 for Injection”, 2 entries
  • “SHR-A1904; Adebrelimab”, 1 entry
  • “SHR-A1904; CAPOX; Adebrelimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.